Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
M&A activity
confidence 95%
filed 2026-07-16
The filing discloses an Amendment to a Merger Agreement dated July 16, 2026, among JFB Construction Holdings, Xtend AI Robotics, Inc., and related entities. The Amendment modifies material terms of a previously disclosed merger transaction, including shortening timelines for consideration schedules, adjusting closing cash thresholds from $110M to $60M, extending the outside closing date to October 31, 2026, and adding lock-up and transfer restrictions. This constitutes a material amendment to an entry into a material definitive agreement under Item 1.01, representing a significant M&A activity disclosure that would materially affect investor assessment of the registrant's strategic direction and transaction terms.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-16
Item 1.01
Uber entered into a Business Combination Agreement on July 16, 2026, to acquire Delivery Hero through a voluntary public takeover offer at €41.50 per share, representing an equity value of €14.8 billion ($14.8 billion). The transaction will expand Uber's delivery platform to 99 markets with combined pro-forma Gross Bookings of $236 billion, funded through existing cash and a committed €14.2 billion bridge credit facility, with expected closing in H2 2027 subject to regulatory approvals and a 50%+ acceptance threshold.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-16
Item 1.01
Braemar Hotels & Resorts entered into an Agreement of Purchase and Sale on July 13, 2026, to sell the Pier House Resort & Spa in Key West, Florida for $190.0 million in cash, and completed the sale of three other hotel properties (The Ritz-Carlton Sarasota, Hotel Yountville, and Bardessono Hotel) for approximately $437.5 million on July 14, 2026. These material dispositions generated approximately $158.2 million in pre-tax gains and significantly reduced the company's asset base while enabling substantial debt repayment of $232.8 million.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-16
Item 8.01
This disclosure describes a statutory scheme of arrangement under English law whereby New Gates (a Bermuda exempted company) becomes the parent holding company of the Gates Group through a redomiciliation. Old Gates shareholders will have their shares cancelled and receive equivalent New Gates shares, with trading transitioning from the old to new entity on the NYSE under the same ticker. This constitutes a material change of control and corporate restructuring meeting the definition of ma_activity, though it is technically a redomiciliation rather than a traditional M&A transaction.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-16
Item 5.01
Kenneth R. Lehman converted 4,000 shares of Preferred Stock into 11,428,000 common shares representing 42.38% of outstanding common stock pursuant to an Exchange Agreement dated April 28, 2026, triggering a material change of control. Lehman obtained the right to designate directors and intends to serve on both the Company's and Bank's Boards.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-16
The filing discloses completion of a strategic transaction on October 31, 2025, whereby Sunoco acquired all issued and outstanding common shares of Parkland Corporation through a court-approved plan of arrangement, making Parkland an indirect wholly owned subsidiary of Sunoco. This is a material acquisition/change of control event. The filing provides audited financial statements of the acquired entity and pro forma combined financial information, which are standard disclosures for completed M&A activity under Item 9.01.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-07-15
EX-99.1
Elemental Royalty has entered into a strategic US$25 million investment package with Quilla Resources to acquire an additional 1.0% NSR royalty over the Pampa Negra and Candelaria concessions at the Chapi Copper Project, plus approximately 9% equity stake in Quilla. This is a material acquisition of royalty rights and equity investment that expands the company's exposure to a producing asset and represents a significant capital deployment, meeting the definition of ma_activity under Item 1.01 (material acquisition).
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-15
Item 1.01
TriCo Bancshares entered into an Agreement and Plan of Reorganization and Merger with First Hawaiian, Inc. on July 12, 2026, whereby TriCo shareholders will receive 2.095 shares of FHI common stock per TriCo share in a multi-step merger transaction, subject to customary closing conditions including regulatory approvals and shareholder votes, with an $80 million termination fee provision.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-15
Item 1.01
First Hawaiian, Inc. entered into an Agreement and Plan of Reorganization and Merger with TriCo Bancshares on July 12, 2026, providing for a two-step merger structure followed by a bank merger, with TriCo shareholders receiving 2.095 shares of FHI Common Stock per share held. This is a material acquisition/change of control transaction requiring stockholder approvals and regulatory clearances from the Federal Reserve, FDIC, and state banking authorities, clearly falling under Item 1.01 M&A activity.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-07-15
EX-99.1
Rubico announced its decision to divest its newbuilding megayacht and exit the megayacht sector, with estimated gross proceeds of €30–€35 million ($34.2–$40 million) and elimination of a €26.5 million capital commitment. This is a material disposition of an asset and a strategic exit from a business line, fitting the definition of ma_activity (Items 1.02, 2.01). The company explicitly states the divestment would release capital for redeployment toward its core tanker business, representing a material change in capital allocation and asset composition.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-15
EX-99.1
Rubico has entered into a share purchase agreement to acquire 100% of the shares of a special purpose vehicle (SPV) that owns a shipbuilding contract for a 47,499 dwt MR tanker newbuilding from Guangzhou Shipyard. The acquisition price is approximately $6.25 million with expected closing by September 30, 2026. This constitutes a material acquisition under Item 1.01 of Form 8-K (or equivalent 6-K disclosure), expanding the company's fleet and increasing its potential gross revenue backlog to approximately $305 million, which would materially affect a reasonable investor's assessment of the registrant's future cash flows and asset base.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-07-15
EX-99.1
TOP Ships announced the sale of 100% of the shares of a special purpose vehicle (SPV) holding a shipbuilding contract for a 47,499 dwt tanker newbuilding to Rubico Inc for approximately $6.25 million, expected to close by September 30, 2026. This constitutes a material disposition of an asset (the SPV and its shipbuilding contract), approved by an independent special committee with a fairness opinion, and would affect a reasonable investor's assessment of the company's fleet composition and capital deployment strategy.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-15
Item 7.01
Worthington Steel announced the opening of the acceptance period for a public delisting tender offer for all outstanding shares of Klöckner & Co SE not already held by Worthington Steel. This constitutes a material acquisition activity—specifically the continuation of a change-of-control transaction. Worthington Steel already holds approximately 62% of Klöckner following completion of its Voluntary Public Takeover Offer on June 3, 2026, and this delisting offer represents the squeeze-out phase to acquire remaining shares at EUR 11.00 per share. This is a material M&A event requiring 8-K disclosure under Item 1.01 or 2.01 framework.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-15
Item 2.01
Nuvalent completed a merger on July 15, 2026, whereby it became a wholly owned subsidiary of Parent following acceptance of all tendered shares in a tender offer and consummation pursuant to Section 251(h) of the DGCL, representing a change of control transaction with an equity value of approximately $10.6 billion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-15
Item 2.01
Catalyst Pharmaceuticals completed a merger transaction in which the Company became a wholly owned subsidiary of Parent, resulting in a change of control. All seven directors resigned and were replaced by three directors of Merger Sub, and Company Common Stock was converted into merger consideration. The Company notified Nasdaq of its intent to delist effective July 16, 2026, and intends to file Form 15 to terminate SEC registration and reporting obligations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-15
Item 8.01
The filing discloses termination of a non-binding letter of intent for a proposed business combination between SC II Acquisition Corp. (a SPAC controlled by T3 Defense's subsidiary) and a payments technology company. Although the LOI was non-binding, the termination of a material acquisition transaction that was previously disclosed and contemplated by the registrant's affiliate constitutes a material M&A event. The disclosure explicitly states the SPAC "is terminating the LOI, effective immediately, as the SPAC does not intend to pursue the Proposed Transaction," which is a clear termination of M&A activity.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-07-15
The 6-K discloses the closing of a patent acquisition by the Company's subsidiary Shuhai Tianjin from Tianjin Qianli Culture Media Co., Ltd. on June 23, 2026, for RMB 7.0 million in consideration, with 1,122,156 restricted Class A ordinary shares issued at US$0.9156 per share. This constitutes a material acquisition transaction that would affect a reasonable investor's assessment of the registrant's asset base and strategic direction in AI technology.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-15
Item 1.01
Item 1.01 discloses entry into a material definitive agreement—specifically the underwriting agreement and related agreements governing the IPO of Samos Energy Acquisition Corporation. While technically an IPO is a capital-raising event rather than a traditional M&A transaction, the Item 1.01 caption and the filing's structure treat this as a material agreement entry. However, the core event is the completion of a $230 million IPO with warrant issuances, which is more accurately characterized as a dilutive equity issuance and capital formation event. The Item 3.02 disclosure of the private placement warrants ($6 million) further supports classification as dilutive_issuance, but Item 1.01's explicit framing as "Entry into a Material Definitive Agreement" and the multiple binding agreements (underwriting, warrant, trust, registration rights, etc.) entered into on July 10, 2026, suggest the filing's primary intent is to disclose material contractual commitments. Given the ambiguity between ma_activity (which typically covers M&A) and dilutive_issuance (which covers unregistered equity sales), and the fact that Item 1.01 is the lead item, ma_activity is the most defensible classification, though dilutive_issuance would also be reasonable for the private placement warrant component.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-15
AXIA Energia completed the sale of its 49% minority equity interests in four special purpose entities engaged in electric power transmission to GEBBRAS Participações Ltda. for BRL 451.4 million on July 15, 2026. This is a material disposition of significant assets (transmission lines spanning ~1,086 km across six Brazilian states) that affects the registrant's capital structure and strategic positioning, warranting classification as a completed M&A activity under Item 1.02 equivalent disclosure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-15
Item 1.01
NextPlat Corp entered into a Membership Interest Purchase Agreement on July 14, 2026, to acquire 100% of Scott's Pharmacy, LLC for $1.5 million in cash. The acquisition is expected to close in Q4 2026 and will add approximately $5.6 million in profitable annual revenue while expanding the PharmcoRx retail footprint into the Pensacola, Florida market.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-07-15
The 6-K discloses entry into an Agreement and Plan of Merger dated July 14, 2026, whereby GrowHub Limited will acquire EnChem America, Inc. (a wholly-owned subsidiary of EnChem Co., Ltd.) for approximately $400 million in equity consideration (142,848,176 Class A ordinary shares representing 85% of fully-diluted shares post-closing). This is a material acquisition transaction requiring disclosure under Item 1.01 of Form 8-K (or equivalent 6-K disclosure). The transaction is subject to customary closing conditions including SEC registration statement effectiveness and NASDAQ listing approval.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-15
The filing discloses completion of an acquisition of approximately 290,000 square meters of land in Spain designated for the JP Financial Arena development. The press release explicitly states "Nomadar Corp. today announced that it has completed the acquisition" and describes this as consolidating "control over a strategic asset" that "strengthens the Company's ability to advance the development of JP Financial Arena." This is a material acquisition of a real estate asset central to the company's strategic platform.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-15
Item 8.01
The Item 8.01 disclosure describes the completion of a strategic business combination between Glucotrack, Inc. and Lōkahi Therapeutics, with Lōkahi becoming the operating and controlling business of the combined company. The press release (Exhibit 99.1) explicitly states "Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination" and references an Agreement and Plan of Merger dated July 14, 2026 (Exhibit 2.1). This is a material acquisition/change of control transaction that fundamentally restructures the company's ownership and operations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-15
The filing discloses completion of Stereotaxis's acquisition of Robocath on July 7, 2026, pursuant to a Share Sale Agreement dated April 14, 2026. The company issued 6,269,628 closing shares and is obligated to pay up to $25 million in earnout consideration upon achievement of regulatory and commercial milestones. This is a material acquisition of 100% of Robocath's share capital and voting power, disclosed under Item 8.01 (Other Events), with extensive risk factors and transaction documents incorporated by reference.
View raw filing on EDGAR →
8-K
M&A activity
confidence 96%
filed 2026-07-15
Item 1.01
Senti Biosciences entered into an Agreement and Plan of Merger on July 14, 2026, whereby a newly formed company controlled by Celadon Partners will acquire substantially all of the company's Gene-Circuit-enabled pipeline assets (including SENTI-202) in exchange for a contingent value right with up to $60 million in milestone payments. The transaction constitutes a material change of control, with Celadon beneficially owning 54.6% to 77.5% of the company's common stock post-closing, and requires stockholder approval.
View raw filing on EDGAR →
6-K
M&A activity
confidence 99%
filed 2026-07-15
GSK announces completion of its acquisition of Nuvalent, Inc., a clinical-stage biopharmaceutical company, for approximately $10.6 billion in aggregate equity value (net $9.4 billion). The announcement explicitly states "GSK completes acquisition of Nuvalent, Inc." and describes the transaction as adding three lung cancer assets to GSK's oncology portfolio, including two assets with FDA Breakthrough Therapy designations and expected 2026 launches with "multi-blockbuster potential." This is a material acquisition completion disclosing a substantial change of control and strategic expansion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-15
Item 1.01
International Stem Cell Corporation entered into a Membership Interest Purchase Agreement on July 10, 2026, to sell 100% of Lifeline Cell Technology, LLC to American Type Culture Collection, Inc. for $25.0 million. This is a material disposition of a subsidiary representing a significant asset sale, with customary closing conditions and stockholder approval requirements, clearly constituting a material M&A transaction under Item 1.01.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-14
Item 1.01
First Bancorp entered into a definitive Agreement and Plan of Merger and Reorganization to acquire First Carolina Bancshares Corporation in a stock-and-cash transaction valued at approximately $166 million, with consideration of 1,967,017 shares and $40 million in cash. The transaction was unanimously approved by both boards and is expected to close in late Q4 2026 or early Q1 2027, subject to customary closing conditions including shareholder and regulatory approvals, and will substantially expand First Bancorp's South Carolina presence and increase its deposit base by over 50%.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 8.01
The filing discloses that Hawthorn Bancshares, Inc. (HBI) has received all required regulatory approvals as of July 10, 2026, to complete its acquisition of FSC Bancshares, Inc. (FBI) pursuant to an Agreement and Plan of Reorganization entered into on April 29, 2026. The transaction is expected to close in Q3 2026, pending FBI shareholder approval and customary closing conditions. This is a material acquisition event that would significantly affect a reasonable investor's assessment of HBI.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-14
Item 1.01
Willis Lease Finance Corporation's subsidiary entered into a definitive Purchase and Sale Agreement on July 10, 2026, to acquire a portfolio of 12 commercial aircraft and 13 spare aircraft engines for approximately $379.3 million, expanding the company's lease portfolio and customer base with closing expected in Q3 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-14
Item 1.01
NextCure entered into a definitive merger agreement with Avere Therapeutics on July 14, 2026, whereby NextCure will acquire Avere in an all-stock transaction. The combined company will operate as Avere Therapeutics, with NextCure stockholders owning approximately 1.21% post-closing, accompanied by a concurrent $320 million private placement financing and expected to close in H2 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-14
Item 7.01
The Company announced formation of a special committee of independent directors to evaluate strategic alternatives "which may include a possible transaction involving the Company." The retention of financial advisor Solomon Partners and legal advisor Willkie Farr & Gallagher LLP to assist with the strategic review process signals active consideration of M&A activity. While no transaction has been entered into yet, the initiation of a formal strategic review process evaluating potential acquisitions, mergers, or other transactions is a material disclosure that would affect a reasonable investor's assessment of the registrant's future direction.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 8.01
The filing discloses a material milestone in a merger transaction: on July 13, 2026, the U.S. Department of Justice granted early termination of the Hart-Scott-Rodino Act waiting period for RE/MAX Holdings' proposed merger with The Real Brokerage Inc. This represents a significant regulatory clearance event in the completion of the contemplated transaction, removing a key closing condition. The merger agreement was entered into on April 26, 2026, and this disclosure documents progress toward consummation of the transaction.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-14
The 6-K discloses a material acquisition transaction: Real Brokerage Inc. entered into a Merger Agreement with RE/MAX Holdings on April 26, 2026, and on July 13, 2026, the U.S. Department of Justice granted early termination of the HSR Act waiting period, clearing a major regulatory hurdle toward completion. The filing provides detailed disclosure of the transaction structure, regulatory approvals obtained, and remaining closing conditions, consistent with Item 1.01 (Material Agreements) or Item 2.01 (Completion of Acquisition or Disposition) disclosure obligations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-14
Item 7.01
This Item 7.01 disclosure concerns a proposed reverse merger transaction between VYNE Therapeutics and Yarrow Bioscience, expected to close approximately July 24, 2026. The filing references a Form S-4 registration statement (File No. 333-294804) containing a proxy statement/prospectus, and the presentation discusses the combined company's strategy, leadership, and clinical pipeline post-transaction. Although styled as a Regulation FD disclosure of an investor presentation, the substance is disclosure of material acquisition activity—specifically a reverse merger that constitutes a change of control.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-14
Item 1.01
Spero entered into an exclusive license agreement with Innovent Biologics on July 8, 2026, acquiring worldwide rights (excluding Greater China) to develop, manufacture, and commercialize SP001, a Phase 2-ready anti-CD40L monoclonal antibody. The transaction includes an upfront payment of $35 million, up to $1.05 billion in milestone payments, and tiered royalties, establishing the foundation of Spero's new immunology pipeline.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-14
EX-99.1
Thomson Reuters has signed a definitive agreement to enter into a joint venture with KKR, selling a 51% stake in its Global Print business for approximately $500 million in gross proceeds while retaining 49% equity interest. This constitutes a material disposition and change of control of a business segment, directly falling under Item 1.01/1.02 (M&A activity). The transaction is substantial, involves a major investment firm, and is expected to close in Q4 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-14
Item 1.01
Diodes Incorporated entered into a definitive Agreement and Plan of Merger on July 10, 2026, to acquire Elevate Semiconductor, Inc. for a $250 million base purchase price plus up to $50 million in earnout payments. The all-cash transaction is expected to contribute approximately $50 million in revenue in the first twelve months post-close and be immediately accretive to revenue, gross margin, and earnings per share.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-14
Item 2.01
flyExclusive completed a material acquisition of Jet.AI's aviation assets on July 14, 2026, pursuant to Amendment No. 5 to the Amended and Restated Merger Agreement executed on July 13, 2026. The transaction involved a merger of Merger Sub into SpinCo (a Jet.AI entity), with SpinCo becoming a wholly owned subsidiary of flyExclusive, and consideration consisting of 7,096,117 shares of Company Common Stock, aircraft, customer relationships, future aircraft delivery positions, SPCX marketable securities, and cash.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-14
Item 2.01
On July 14, 2026, Ligand Pharmaceuticals completed its acquisition of XOMA Royalty Corporation, with stockholders receiving $39.00 per share in cash plus contingent value rights tied to pending litigation proceeds. The transaction constitutes a material change of control and merger completion, with the company's stock delisted from Nasdaq and registration to be terminated via Form 15.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 1.01
Ligand Pharmaceuticals completed its acquisition of XOMA Royalty Corporation on July 14, 2026, for $39.00 per share in cash (approximately $739 million equity value) plus contingent value rights. The transaction doubles Ligand's royalty portfolio from approximately 100 to over 200 assets, adds seven commercial products and 14 late-stage development programs, and is expected to be accretive to earnings per share by $0.50 and $1.50 in 2026 and 2027 respectively.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-14
EX-99.1
Navigator Holdings announced the signing of definitive agreements to sell eight gas carriers and its shareholding in the Unigas Joint Venture for approximately $183 million to existing Unigas partners. This is a material disposition transaction involving the sale of significant fleet assets and a joint venture stake, expected to close by Q4 2026. The transaction represents a substantial capital event affecting the company's fleet composition and financial position.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-14
Item 1.01
Jaguar Health's subsidiary Napo entered into a new three-year manufacturing and supply agreement with Alivus on July 9, 2026, to continue supplying crofelemer for Mytesi®, the company's FDA-approved prescription drug product. This is a material definitive agreement that secures the supply chain for the company's primary commercial product and includes minimum purchase commitments with potential financial obligations. While this is a renewal rather than a new relationship, the binding three-year commitment with specified minimum quantities and financial penalties for shortfalls constitutes a material agreement affecting the company's operational and financial obligations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 2.01
Apollo-managed funds completed the acquisition of Emerald Holding, Inc. on July 14, 2026, for $5.03 per share in cash, resulting in a change of control and the cessation of Emerald's NYSE trading. The transaction also included the acquisition of Questex, LLC, creating a combined B2B experiential events and media platform, with Emerald becoming a wholly-owned subsidiary and its board members ceasing service.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 2.01
Ares Real Estate funds completed an all-cash acquisition of Whitestone REIT for $19.00 per share, valued at approximately $1.7 billion, resulting in a change of control and the company's delisting from NYSE. The transaction included the merger of Whitestone with Merger Sub and the merger of Whitestone's operating partnership with Merger OP, with Whitestone ceasing to exist as a publicly traded entity.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 1.01
Strategic Storage Trust VI, Inc. entered into a definitive Agreement and Plan of Merger on July 14, 2026, to acquire Strategic Storage Growth Trust III, Inc. in an all-stock transaction. The merger combines two SmartStop-sponsored REITs and includes acquisition of 12 wholly-owned self-storage facilities, 50% equity interests in three unconsolidated real estate ventures, and beneficial interests in three DST-sponsored programs, with a combined company expected to have a total asset value of approximately $1.2 billion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-14
Item 1.01
Research Alliance Corp IV entered into multiple material definitive agreements in connection with its initial public offering, including an Underwriting Agreement, Investment Management Trust Agreement, Registration and Shareholder Rights Agreement, and Private Placement Shares Purchase Agreement. These agreements establish the company's capitalization and governance framework for pursuing a business combination.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-14
EX-99.1
The press release announces termination of a letter of intent for the acquisition of AI Financial Corporation's subsidiary Alt5 Sigma Canada, Inc. This is a material M&A event — the termination of a proposed transaction. The statement from Chief Strategy Officer Matthew Nicoletti explicitly states "Perpetuals has decided not to further pursue the acquisition" and "the earlier letter of intent has been terminated," which constitutes a material change in the status of a contemplated acquisition that would affect investor assessment of the company's strategic direction and capital allocation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-14
Item 8.01
Churchill Capital Corp XI and Agility Robotics announced the confidential submission of a draft Form S-4 registration statement on July 13, 2026, in connection with their previously disclosed Merger Agreement. The filing discloses a material acquisition/business combination transaction expected to close in 2026, with approximately $620 million in gross proceeds, creating a publicly listed pure-play humanoid robotics company. This is a clear entry into a material merger and change of control transaction requiring shareholder approval.
View raw filing on EDGAR →
6-K
M&A activity
confidence 85%
filed 2026-07-14
EX-99.1
Youxin Technology announced a non-binding term sheet to make a strategic investment of US$20 million in RiverBit Holding Limited to acquire a 10% equity interest upon achievement of operating milestones (2,000 daily users and US$100 million daily trading volume within three months of launch). Although non-binding and contingent on due diligence and definitive agreements, this represents a material acquisition of a minority equity interest in a third party, which falls within the scope of M&A activity disclosures. The investment amount and strategic nature would affect a reasonable investor's assessment of the company's capital allocation and business strategy.
View raw filing on EDGAR →